English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives Sensitive and accurate techniques for early detection of prostate cancer, which has a good chance for successful treatment if detected early, are of utmost value. Our aim is to develop a sensitive chronoimpedimetric biosensor for detection of circulating prostatic tumor cells (CTCs) with an aptamer selective for prostate specific membrane antigen (PSMA). Methods Thiolated PSMA-specific aptamer was immobilized on the gold nanoparticle modified carbon screen-printed electrodes. After characterization with cyclic voltammetry and electrochemical impedance spectrometry, scanning electron microscopy and atomic force microscopy studies were conducted to confirm the modifications. LNCaP cells (androgen-sensitive human prostate adenocarcinoma cells), were then added to the serum samples and chronoimpedimetric detection of CTCs in samples were performed. Results Our study showed one cell detection capability in real serum samples with a linear range from 1 to 40 cells/mL. The incubation time was 130 s. LOD was found to be 0.62 cells/mL and relative standard deviations were lower than 2% RSD. Reproducibility tests indicated a regression coefficient as R 2  = 0.9963 ± 0.0178. Conclusions This new biosensor enables rapid, accurate, precise, reproducible and highly sensitive detection of PSMA on CTCs in prostate cancer and paves the way to new diagnostic applications and research-based studies.

Detection of circulating prostate cancer cells via prostate specific membrane antigen by chronoimpedimetric aptasensor